Literature DB >> 12031877

Pm-149 DOTA bombesin analogs for potential radiotherapy. in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2).

Fang Hu1, Cathy S Cutler, Timothy Hoffman, Gary Sieckman, Wynn A Volkert, Silvia S Jurisson.   

Abstract

Promethium-149 (149Pm) is one of only three radiolanthanides that can be prepared in no carrier added concentrations. This high specific activity radiolanthanide is thus suitable for targeting limited numbers of specific receptors found on many tumor cells. Promethium-149 is a moderate energy beta(-) emitter (1.07 MeV (95.9%)) with a half-life of 2.21 days. Pm-149 also emits a low abundance of an imageable gamma ray (286 keV (3%)) that may allow in vivo tracking of the therapeutic dose. The 149Pm and Sm complexes with the DO3A-amide chelator with zero and three carbon spacers to the bombesin peptide analog BBN(7-14)NH(2) were synthesized and characterized. The Sm complexes were synthesized for macroscopic characterization purposes (ESI-MS, in vitro cell binding) since no stable isotopes of Pm are known. The biological properties of the 149Pm, 153Sm and 177Lu-DO3A-amide-betaAla-BBN complexes were compared in normal mouse biodistribution studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12031877     DOI: 10.1016/s0969-8051(02)00290-1

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  7 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

Review 2.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

3.  166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel.

Authors:  S Thompson; B Ballard; Z Jiang; E Revskaya; N Sisay; W H Miller; C S Cutler; E Dadachova; L C Francesconi
Journal:  Nucl Med Biol       Date:  2013-12-30       Impact factor: 2.408

Review 4.  Cutting edge rare earth radiometals: prospects for cancer theranostics.

Authors:  Alexander W E Sadler; Leena Hogan; Benjamin Fraser; Louis M Rendina
Journal:  EJNMMI Radiopharm Chem       Date:  2022-08-26

5.  Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.

Authors:  Jered C Garrison; Tammy L Rold; Gary L Sieckman; Farah Naz; Samantha V Sublett; Said Daibes Figueroa; Wynn A Volkert; Timothy J Hoffman
Journal:  Bioconjug Chem       Date:  2008-08-20       Impact factor: 4.774

Review 6.  Targeting prostate cancer with radiolabelled bombesins.

Authors:  Theodosia Maina; Berthold Nock; Stephen Mather
Journal:  Cancer Imaging       Date:  2006-11-08       Impact factor: 3.909

7.  Synthesis and Preliminary Biological Evaluations of Fluorescent or 149Promethium Labeled Trastuzumab-Polyethylenimine.

Authors:  Jonathan Fitzsimmons; Tapan Nayak; Cathy Cutler; Robert Atcher
Journal:  Biomedicines       Date:  2015-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.